Bempedoic Acid Powder is a well-defined small-molecule fatty acid derivative. Its chemical structure can be considered a substituted long-chain dicarboxylic acid analog, containing a hydrophobic carbon chain backbone and multiple polar functional groups, including carboxyl and hydroxyl groups. This combination of a hydrophobic chain and polar end groups confers good biocompatibility and membrane permeability. From a structural design perspective, beempedoic acid is not a traditional direct-acting inhibitor but rather a prodrug. It requires specific enzyme catalysis to be converted into its active form in vivo before it can exert its effect. Its molecular backbone contains substituents at specific positions and a specific stereoconfiguration, enabling it to be recognized and converted by specific enzymes in the liver, thereby achieving tissue-selective activation.
In terms of physicochemical properties, beempedoic acid typically appears as a white or off-white crystalline powder, is chemically stable, and is not easily degraded under normal storage conditions. It exhibits good solubility in organic solvents but limited solubility in water; however, better dispersibility can be achieved through salt formation or formulation optimization. The carboxyl group in the molecule confers it some ionization ability, which helps it form a stable form in the physiological environment. As a structurally optimized metabolic regulatory molecule, Bempedoic Acid embodies the design philosophy of achieving a balance between targeted activation and safety through structural modification at the medicinal chemistry level, providing an important reference for the development of lipid metabolism regulatory compounds.
Shaanxi Medibridge Biotech Co., Ltd. focuses on the supply of pharmaceutical raw materials and research-use compounds. We support customers with stable quality, clear specification communication, flexible packaging options, and document-related support for different project stages.
COA
|
|
||
|
Product Name |
CAS Number |
Batch Number |
|
Bempedoic Acid Powder |
738606-46-7 |
MB2606130145 |
|
Manufacturer Date |
Analysis Date |
Expiry Date |
|
2026/6/13 |
2026/6/15 |
2028/6/15 |
|
Sample Qty Base |
Packing |
Test Method |
|
100KGS |
25KG/drum |
HPLC |
|
|
||
|
Item |
Standard |
Results |
|
Appearance |
Off-White Powder |
Conform |
|
Odor |
Characteristic |
Conform |
|
Assay |
≥98.0% |
98.57% |
|
Particle Size |
100% pass 80mesh |
Conform |
|
Moisture |
<5.0% |
Conform |
|
Ash Content |
<4.0% |
Conform |
|
Solvent Residue |
Eur.Pharm |
Conform |
|
Total Heavy Metals |
<10 ppm |
Conform |
|
Arsenic |
<1.0 ppm |
Conform |
|
Lead |
<1.0 ppm |
Conform |
|
Mercury |
<0.5 ppm |
Conform |
|
DDT |
<0.2ppm |
Conform |
|
E. Coli |
Negative |
Negative |
|
GMO Status |
Complies |
GMO Free |
|
Irradiation |
Complies |
Irradiation Free |
|
Conclusion |
The batch conforms to the IN-HOUSE standard |
|
|
|
||
Mechanism of Action & Molecular Target
ATP Citrate Lyase (ACL) Inhibitor
Bempedoic acid is a prodrug that is rapidly activated in the liver to inhibit **ATP Citrate Lyase (ACL)**, a key rate-limiting enzyme upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. By inhibiting ACL, it blocks the conversion of citrate to acetyl-CoA, thereby halting endogenous cholesterol synthesis in hepatic cells.
Up-regulation of LDL Receptors (LDLR)
The reduction of intracellular cholesterol in hepatocytes triggers a feedback mechanism that increases the expression and activity of Low-Density Lipoprotein Receptors (LDLR) on the liver cell surface, accelerating the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream.
Pharmacology & Tissue Selectivity
Liver-Specific Activation
As an inactive prodrug, Bempedoic Acid requires conversion into its active metabolite (ETC-1002-CoA) by the enzyme Very Long-Chain Acyl-CoA Synthetase-1 (ACSVL1). ACSVL1 is predominantly expressed in the liver but is virtually absent in skeletal muscle.
Resolution of Statin-Associated Muscle Symptoms (SAMS)
Statins often induce statin-associated muscle symptoms (SAMS, such as myalgia and muscle weakness) by inhibiting cholesterol synthesis and mitochondrial function in skeletal muscle. Because skeletal muscle lacks the ACSVL1 enzyme, Bempedoic Acid cannot be converted into its active form in muscle tissue, thereby completely avoiding skeletal muscle toxicity and offering an ideal option for statin-intolerant patients.
Clinical Efficacy & Cardiovascular Outcomes
Potent Reduction of LDL-C and hs-CRP
As monotherapy, Bempedoic Acid reduces LDL-C levels by approximately 15% to 25%. When combined with ezetimibe or statins, it demonstrates robust synergistic lipid-lowering effects (reducing LDL-C by up to 35%–40% when co-administered with ezetimibe). Additionally, it significantly lowers high-sensitivity C-reactive protein (hs-CRP) by 20% to 30%, providing extra anti-inflammatory and anti-atherosclerotic benefits.
Cardiovascular Benefits Proven by CLEAR Outcomes
The landmark CLEAR Outcomes clinical trial confirmed that Bempedoic Acid significantly reduces the risk of Major Adverse Cardiovascular Events (MACE, including myocardial infarction and coronary revascularization) in statin-intolerant, high-risk cardiovascular patients.
Relationship to Other Lipid-Lowering Pathways
Bempedoic acid, statins, and ezetimibe act at different points in cholesterol metabolism:
|
Agent or class |
Main target or pathway |
|
Bempedoic acid |
Inhibits ATP-citrate lyase (ACLY) after activation in the liver, acting upstream in cholesterol synthesis |
|
Statins |
Inhibit HMG-CoA reductase |
|
Ezetimibe |
Inhibits intestinal cholesterol absorption |
Safety and Interactions
Current U.S. prescribing information highlights increased blood uric acid and gout risk, as well as tendon injury or rupture. In the CLEAR Outcomes trial, gout and cholelithiasis occurred more often in the bempedoic acid group; labeling also reports findings such as elevated liver enzymes and anemia. Activation primarily in the liver does not mean the medicine is free of systemic adverse effects. Safety must be assessed in the context of the individual patient and their other medications.
FAQ
Is bempedoic acid safe to take?
Bempedoic acid is generally considered safe and effective for lowering LDL ("bad") cholesterol, especially for adults who cannot tolerate statins.
Is bempedoic acid available in Singapore?
Bempedoic acid is a prescription oral medicine used to lower low-density lipoprotein cholesterol and reduce cardiovascular risks, especially for patients who cannot tolerate statins.
What is bempedoic acid used for?
Bempedoic acid is a prescription oral tablet used to lower low-density lipoprotein (LDL) or "bad" cholesterol and reduce the risk of heart attacks in adults.
Is bempedoic acid better than a statin?
Bempedoic acid is not generally "better" than a statin, but it is a valuable and effective alternative for people who cannot tolerate statins.
If you are looking for a high-quality Bempedoic Acid Powder manufacturer with whom you can establish a long-term, stable partnership, then Shaanxi Medibridge Biotech Co., Ltd. would be your best business partner. Don't hesitate to contact us at hi@medibridgeapi.com.
Hot Tags: bempedoic acid powder, China bempedoic acid powder manufacturers, suppliers, factory
